November 4, 2021
Mitsubishi Tanabe Pharma revealed on November 2 that it has entirely discontinued the development of its plant-derived seasonal influenza vaccine MT-2271. It now plans to withdraw its regulatory application filed in Canada and call off a PIII program in Europe...read more